Vesselin T. Tomov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vesselin T. Tomov has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Ajinkya Pattekar
Department of Medicine, Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
2 shared publicationsChi Wai Lau
Department of Medicine, Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
2 shared publicationsOlesya Palko
Department of Medicine, Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Orthopedic Surgery, Montefiore Medical Center, Bronx, NY, USA
2 shared publications- Adam Williams
Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
1 shared publication Ali Naji
Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
1 shared publicationBertram Bengsch
Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
1 shared publication
Latest Publications
- Open Access
- 8 September 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (12)
The miR-181 family regulates colonic inflammation through its activity in the intestinal epithelium
The intestinal epithelium is a key physical interface that integrates dietary and microbial signals to regulate nutrient uptake and mucosal immune cell function. The transcriptional programs that regulate intestinal epithelial cell (IEC) quiescence, proliferation, and differentiation have been well characterized. However, how gene expression networks critical for IECs are posttranscriptionally regulated during homeostasis or inflammatory disease remains poorly understood. Herein, we show that a conserved family of microRNAs, miR-181, is significantly downregulated in IECs from patients with inflammatory bowel disease and mice with chemical-induced colitis. Strikingly, we showed that miR-181 expression within IECs, but not the hematopoietic system, is required for protection against severe colonic inflammation in response to epithelial injury in mice. Mechanistically, we showed that miR-181 expression increases the proliferative capacity of IECs, likely through the regulation of Wnt signaling, independently of the gut microbiota composition. As epithelial reconstitution is crucial to restore intestinal homeostasis after injury, the miR-181 family represents a potential therapeutic target against severe intestinal inflammation.
- 8 September 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (12)
Open AccessThe miR-181 family regulates colonic inflammation through its activity in the intestinal epithelium
The intestinal epithelium is a key physical interface that integrates dietary and microbial signals to regulate nutrient uptake and mucosal immune cell function. The transcriptional programs that regulate intestinal epithelial cell (IEC) quiescence, proliferation, and differentiation have been well characterized. However, how gene expression networks critical for IECs are posttranscriptionally regulated during homeostasis or inflammatory disease remains poorly understood. Herein, we show that a conserved family of microRNAs, miR-181, is significantly downregulated in IECs from patients with inflammatory bowel disease and mice with chemical-induced colitis. Strikingly, we showed that miR-181 expression within IECs, but not the hematopoietic system, is required for protection against severe colonic inflammation in response to epithelial injury in mice. Mechanistically, we showed that miR-181 expression increases the proliferative capacity of IECs, likely through the regulation of Wnt signaling, independently of the gut microbiota composition. As epithelial reconstitution is crucial to restore intestinal homeostasis after injury, the miR-181 family represents a potential therapeutic target against severe intestinal inflammation.
- Open Access
- 1 January 2021
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 11 (5) , 1267-1289
Norovirus-Specific CD8+ T Cell Responses in Human Blood and Tissues
- 1 January 2021
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 11 (5) , 1267-1289
Open AccessNorovirus-Specific CD8+ T Cell Responses in Human Blood and Tissues
- Open Access
- 1 January 2020
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 10 (2) , 422-423
Towards a Comprehensive Understanding of Human Norovirus Immunity
- 1 January 2020
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 10 (2) , 422-423
Open AccessTowards a Comprehensive Understanding of Human Norovirus Immunity
- Top Cited Papers
- 19 July 2017
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 14 (10) , 573-584
Gut microbiota and IBD: causation or correlation?
Alterations in intestinal microbial composition have long been associated with chronic inflammation; however, a definitive cause–effect relationship between dysbiosis and IBD has been difficult to prove, especially in humans Dysbiosis alters not only the composition of the intestinal microbiota, but also its metabolome, thereby exerting a wide range of effects on the host While the microbiota plays a key pathogenic role in IBD, chronic inflammation, in turn, promotes dysbiosis by altering the oxidative and metabolic environment of the gut Animal studies have elucidated key immunological pathways in the pathogenesis of IBD, established both pro-inflammatory and anti-inflammatory roles of the gut microbiota, and shown that the gut microbiota is indispensable for pathogenesis in most colitis models Microbial-based treatments will likely have a role in the future management of IBD; however, many questions remain regarding the bacterial composition, timing of administration, and patient selection for such therapies
- 19 July 2017
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 14 (10) , 573-584
Top Cited PapersGut microbiota and IBD: causation or correlation?
Alterations in intestinal microbial composition have long been associated with chronic inflammation; however, a definitive cause–effect relationship between dysbiosis and IBD has been difficult to prove, especially in humans Dysbiosis alters not only the composition of the intestinal microbiota, but also its metabolome, thereby exerting a wide range of effects on the host While the microbiota plays a key pathogenic role in IBD, chronic inflammation, in turn, promotes dysbiosis by altering the oxidative and metabolic environment of the gut Animal studies have elucidated key immunological pathways in the pathogenesis of IBD, established both pro-inflammatory and anti-inflammatory roles of the gut microbiota, and shown that the gut microbiota is indispensable for pathogenesis in most colitis models Microbial-based treatments will likely have a role in the future management of IBD; however, many questions remain regarding the bacterial composition, timing of administration, and patient selection for such therapies